Aandeel DOVA DOVA PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Dova Pharmaceuticals, Inc.

Aandelen

DOVA

US25985T1025

Vertraagde tijd Nasdaq
Andere beurzen
 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
- USD -.--% Intraday-grafiek van Dova Pharmaceuticals, Inc. -0,07% +269,92%
2019 Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
2019 Transcript : Dova Pharmaceuticals, Inc. - Special Call

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase
Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index
Dova Pharmaceuticals, Inc. Announces Executive Changes
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index
WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers DOVA
  4. Nieuws Dova Pharmaceuticals, Inc.
  5. Andere talen